Skip to main content
Mabion S.A. logo

Mabion S.A. — Investor Relations & Filings

Ticker · MAB ISIN · PLMBION00016 LEI · 259400KG5JVQPPZL6X53 WAR Manufacturing
Open in API
Filings indexed 1,002 across all filing types
Latest filing 2022-04-22 Audit Report / Informat…
Country PL Poland
Listing WAR MAB

About Mabion S.A.

https://www.mabion.eu/en/

Mabion S.A. is an integrated Contract Development and Manufacturing Organization (CDMO) that provides end-to-end services for the development and manufacturing of protein-based biotherapeutics. The company specializes in monoclonal antibodies and biosimilars, offering a complete workflow from cell line development and banking to process optimization and large-scale GMP manufacturing. Core competencies include upstream processing using mammalian cell cultures, downstream purification involving chromatography and viral clearance, and technology transfer for scale-up. Mabion partners with pharmaceutical and biotechnology companies to support both clinical and commercial supply, streamlining the path from gene to final drug product.

Recent filings

Filing Released Lang Actions
Oświadczenie Zarządu w sprawie rzetelności sporządzenia sprawozdania finansowego
Audit Report / Information Classification · 95% confidence The provided document text consists entirely of XML digital signature blocks (Signatures) containing metadata, certificates, and digests. Crucially, the `Reference` elements within the signatures point to a file named "Oswiadczenie Zarzadu ws. rzetelnosci sprawozdan za rok 2022.xhtml". This Polish phrase translates to "Management Board Statement on the reliability of the reports for the year 2022". This type of statement, often accompanying annual or interim financial reports, relates to management's assertion regarding the accuracy of the financial statements. Since the document itself is just the signature block and not the full report or a general announcement, and it specifically relates to the reliability of reports, it strongly suggests this is part of the formal submission process for financial reporting. Given the context of financial reporting reliability statements, the closest fit among the provided codes is related to management's explanation or governance/audit assurance. - **AR (Audit Report / Information)**: This covers audit reports and stress tests. A management statement on reliability is closely related to the audit process. - **MDA (Management Reports)**: This covers management's detailed explanation of financial results and outlook. - **CGR (Governance Information)**: This covers internal rules and board structure. The specific reference to the 'reliability of reports' points most directly to the assurance provided by management, which is a key component often reviewed alongside the Audit Report or included in the Management Discussion & Analysis (MDA). However, without the actual content of the 'Oswiadczenie Zarzadu' (which is referenced but not present), classifying it as a full report (10-K, IR) is incorrect based on Rule 2 (Menu vs Meal). Since this is a formal, signed statement related to the integrity of financial reporting, it fits best under the umbrella of formal assurance/audit information or management reporting. Considering the content is a formal, signed declaration about the *reliability of reports*, it is highly indicative of the assurance section typically found in or accompanying the **Audit Report / Information (AR)** or the **Management Reports (MDA)**. Given the explicit focus on 'rzetelnosci sprawozdan' (reliability of reports), AR is a slightly stronger fit than general MDA, as it pertains to the formal verification/assurance process. If this were an announcement *about* the filing, RPA would apply, but the document *is* the signature block for the statement itself, implying it is the content being filed or attached. I will classify it as **AR** due to the explicit reference to the reliability statement for reports. FY 2022
2022-04-22 Polish
Oświadczenie Zarządu w sprawie rzetelności sporządzenia sprawozdania finansowego
Management Reports Classification · 95% confidence The document text is a formal declaration ('OŚWIADCZENIE ZARZĄDU') by the Management Board of MABION S.A. regarding the annual financial statements and the management report for the year 2021. This statement confirms that the financial statements comply with accounting principles and that the management report accurately reflects the company's performance and risks. This type of declaration, which is a mandatory component accompanying the annual financial reports but is not the full report itself, aligns closely with the content found in comprehensive annual filings or management disclosures. Given the options, it is a formal statement about the annual results and management's view, which is often included in or closely related to the Annual Report (10-K) or Management Discussion & Analysis (MDA). However, since it is a specific, signed declaration about the accuracy of the annual report and management report, it functions as a key component of the overall annual disclosure package. Since it is not the full 10-K, and it is a management statement about the results, MDA is a strong candidate. Alternatively, because it is a formal statement accompanying the annual filing, and the document is very short (784 chars), it could be considered a Regulatory Filing (RNS) if it were a standalone announcement, but its content is highly specific to the annual reporting process. Given the content focuses on the 'roczne sprawozdanie finansowe' (annual financial statement) and 'Sprawozdanie Zarządu z działalności' (Management Report on activities), it best fits the scope of Management Reports (MDA) or is a component of the Annual Report (10-K). As it is a specific management certification rather than the full report or a general earnings release, MDA (Management's detailed explanation of financial results, business trends, and outlook) is the most appropriate fit for this specific management certification regarding the annual results.
2022-04-22 Polish
Pismo Prezesa Zarządu
Regulatory Filings Classification · 85% confidence The provided document text consists almost entirely of XML digital signature blocks (Signature, SignedInfo, KeyInfo, X509Certificate, etc.). This structure is typical for digitally signed regulatory filings or official documents in certain jurisdictions, often accompanying the main report. The content itself does not describe financial results, management changes, or meeting details. The presence of Polish identifiers (PL, Asseco Data Systems S.A., Krzystof Kaczmarczyk) and the file reference 'List_Prezesa.xhtml' (List of the President/CEO) suggests an official declaration or filing. Since the text is not the report itself but rather the cryptographic wrapper, and it doesn't fit specific categories like DIRS (Director's Dealing) or DIV (Dividend Notice), the most appropriate general classification for an official, signed, but otherwise uncategorized regulatory artifact is 'Regulatory Filings' (RNS). The document length (5728 chars) is substantial enough that it's unlikely to be a simple RPA announcement, suggesting it is the signed component of a larger filing.
2022-04-22 Polish
Pismo Prezesa Zarządu
Management Reports Classification · 95% confidence The document is a letter from the CEO (Krzysztof Kaczmarczyk) addressed to shareholders and investors, serving as an introduction to the 2021 Annual Report. It discusses strategic choices, the Novavax contract, financial performance highlights, and future outlook. While it contains financial data, it is a narrative management commentary/letter rather than the full audited financial statements or the 10-K report itself. According to the classification guidelines, this type of management commentary/discussion is best categorized as a Management Report (MDA). FY 2021
2022-04-22 Polish
Dopuszczenie i wprowadzenie akcji zwykłych na okaziciela serii S Spółki do obrotu giełdowego - Content (PL)
Share Issue/Capital Change Classification · 95% confidence The document text is very short (948 characters) and announces a decision made by the Management Board of the Warsaw Stock Exchange (GPW) regarding the admission and introduction of new series of shares (Series S) into stock exchange trading. This is a formal regulatory announcement concerning the listing and trading of securities, specifically mentioning the GPW and KDPW (National Securities Depository). This type of announcement, which details the official listing status of shares, fits best under the general category of regulatory filings that are not specifically covered by other codes like DIV, SHA, or POS, which deal with the company's direct actions regarding dividends, share issues, or repurchases. Since it is a formal notice about market operations and listing approval, and it is not a comprehensive report, the most appropriate classification is the general Regulatory Filings category (RNS), as it is a regulatory communication. However, upon reviewing the definitions, the content is specifically about the admission of shares to trading, which is a capital market event. While RNS is a fallback, the content is highly specific to the listing process. None of the other codes perfectly match 'Stock Exchange Listing Approval Notice'. SHA covers 'Share Issue/Capital Change', which is related but usually refers to the company's decision to issue shares, not the exchange's approval for trading. Given the nature of the announcement (official notice from the exchange regarding trading admission), RNS serves as the best fit among the provided options for a specific regulatory notice that isn't a full report or a direct company action like a dividend declaration.
2022-04-20 Polish
Wpis Spółki jako wytwórcy substancji czynnej SARS-CoV-2 rS do Rejestru Głównego Inspektoratu Farmaceutycznego - Content (PL)
Regulatory Filings Classification · 100% confidence The document is written in Polish and references previous current reports ('raport bieżący') regarding a manufacturing agreement for a COVID-19 vaccine antigen with Novavax. The core information is that the company (Mabion S.A.) received notification on April 19, 2022, that its activity as a manufacturer of the active substance (SARS-CoV-2 rS) was entered into the National Register of Manufacturers, Importers, and Distributors of Active Substances by the Chief Pharmaceutical Inspectorate (GIF). This is a specific regulatory update concerning manufacturing authorization, which is a type of official announcement. It is not a full annual report (10-K), an earnings release (ER), or a transcript (CT). Since it details a specific regulatory/legal step related to operations and compliance, it fits best under the general 'Regulatory Filings' category (RNS) as it is a specific, non-standard announcement that doesn't fit the other specialized codes like DIRS, DIV, or CAP. Given the context of regulatory compliance updates, RNS is the most appropriate fallback.
2022-04-19 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.